Market Highlights
According to MRFR analysis, Antibiotics Market overviewis expected to register a CAGR of 4.8% during the forecast period and was valued at USD 51,835 Million in 2018.
Top Boosters and Impediments
Antibiotics are witnessing robust demand in line with the rapid escalation in a variety of infectious diseases. Some of the most common infectious diseases across the globe are pneumonia, lower respiratory infections, tuberculosis, and malaria. The heavy burden of these diseases is prompting government as well as non-government agencies to spend substantially on R&D initiatives to come up with novel antibiotics. Introduction of favorable regulatory policies that expedite research funding and drug approval process also accelerate market growth.
Pharmaceutical firms are increasingly putting efforts on developing novel therapies for effective treatment of infectious diseases, which should work in favor of the antibiotics market. Strong support from the government in the form of legislations like REVAMP Act and the GAIN Act also facilitate the approval process and the resultant increase in introduction of antibiotic drugs in the market will further bolster business growth.
Market Segmentation:
To offer a detailed report on the antibiotics market, MRFR has profiled drug class, spectrum of activity, drug origin, and end-user.
Drug class specified in the MRFR report are Sulfonamides, Cephalosporins, Carbapenem, Aminoglycosides, Macrolides, Penicillin, and more. Carbapenem form the fastest expanding segment in the market, owing to the rising cases of pneumonia, bloodstream infections and UTIs that require these classes of antibiotics.
Spectrum of activity-based segments include Narrow-spectrum Antibiotic as well as Broad-spectrum Antibiotic. Broad-spectrum antibiotics are the top segment in the market, as these types are used against a vast range of disorders, which ultimately fight antimicrobial resistance. Some of the top examples of these types are cephalosporins, quinolones and aminoglycosides.
Drug origin-wise, the market caters to synthetic, semi-synthetic and natural. Semi-synthetic segment should soar at the fastest rate in the years ahead since these are derived mostly from natural antibiotics with slightly different but beneficial. These also act against the bacteria resistant to original compounds, contain a broad-spectrum of activity, and the chances of side-effects are quite less. Ampicillin drug is one of the top examples of semi-synthetic antibiotics.
Top market end-users are research organizations, hospitals & clinics and more. Hospitals & clinics form the biggest segment as a high number of treatments as well as procedures take place in these healthcare settings.
Key Players
Some of the key players in the Global Antibiotics Market are Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Astellas Pharma Inc. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Abbott Laboratories (US), GlaxoSmithKline PLC (UK), Sanofi (France), Bayer AG (Germany), Eli Lilly and Company (US), and Merck & Co., Inc. (US).
Regional Analysis
North America and APAC or Asia Pacific along with Europe and MEA or Middle East and Africa are the key markets for antibiotics worldwide.
Americas: The largest regional market. Rising growth in the pharmaceutical sector, increasing adoption of antibiotics, are the significant factors that would drive the growth of the sharing antibiotics in this region. This region is expected to increase its market share in the future, owing to the increased adoption of antibiotics. As per the Centers for Disease Control and Prevention (CDC), in 2019, 8,920 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.7 cases per 100,000 population. Market players in the country are extensively focusing on the development of novel anti-infective drugs, and they are also adopting various growth strategies. Thus, this is likely to drive the market in the country. the demand for antibiotic drugs to treat the nosocomial infections caused due to COVID-19 virus also increased in the country.
Europe has emerged as one of the leading consumers of antibiotics, in view of the rising burden of infectious diseases and the escalating consumption of generic medicines. Surge in product innovations by the local vendors for treating severe bacterial disorders along with the huge numbers of clinical trials taking place in the region also add to the market value. Additionally, the rising prevalence of diseases such as HIV/AIDS, pneumonia, malaria, and tuberculosis, combined with the considerable spending on R&D activities by the biotech firms will also benefit the European market in the future. Focus on discovering advanced molecules and the increasing healthcare expenditure are a few other growth boosters in the regional market.
Asia Pacific is presumed to be the fastest-advancing market for antibiotics in the following years, considering the soaring consumption of different antibiotics and the booming sales of over-the-counter drugs.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
